Company intelligence / Profile preview
Mazal Plant Pharmaceuticals
Delaware, United Statesmazal.cc ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Mazal developed three main programs using a proprietary whole plant approach. The lead asset, MAHDL01 for cholesterol management, received FDA IND clearance in May 2005 and was preparing to enter Phase I/II trials at that time. No published results or further clinical progress are available after that date.
- Therapeutic areas
- OncologyCardiovascularNeurology
- Modalities
- Whole plant pharmaceuticals (plant-derived drug compositions)Small molecules derived from whole plants
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Mazal Plant Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mazal Plant Pharmaceuticals.